Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
The Obesity Revolution
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

With its silence on key questions, Omeros raises doubts about its rare disease drug

  • Adam Feuerstein

By Adam Feuerstein Aug. 22, 2017

Reprints
IV Drip
APStock

The Seattle biotech Omeros (OMER) has long told investors it has a potential blockbuster on its hands in OMS721, an experimental drug aimed at treating patients with rare blood and kidney diseases.

So why won’t the company answer questions about its clinical data?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

‘I fear the long-term effects’: Before his death, a…
‘I fear the long-term effects’: Before his death, a nurse warned of the pandemic’s toll on…
I helped write the manual for diagnosing mental illness.…
I helped write the manual for diagnosing mental illness. Donald Trump doesn’t meet the criteria
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War
J&J loses a patent battle in India over a…
J&J loses a patent battle in India over a crucial tuberculosis drug

Comments are closed.

Recommended Stories